US biotech Celsion, Inc. will design and conduct a clinical trial in partnership with Oxford University (UK) to evaluate the use of its heat-activated drug, Thermodox, and ultrasound-guided high intensity focused ultrasound in treating patients with metastatic liver cancer.  Patient treatments are expected to begin later this year. The study is supported by the National Institute for Health Research Oxford Biomedical Research Centre. It will be conducted as a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering and the Oxford University Hospitals NHS Trust.

 

READ PRESS RELEASE

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
434.220.4993
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Email